The Liverpool School of Tropical Medicine (LSTM) has announced a new partnership worth £4.5 million to tackle neglected tropical diseases (NTDs).

The announcement, made by LSTM, commits the funding to a collaborative programme aimed at addressing a group of diseases that predominantly affect populations in low- and middle-income countries. The £4.5 million figure represents the total value of the partnership as stated by the institution.

LSTM, founded in 1898, is one of the UK's oldest research institutions dedicated to tropical medicine, and neglected tropical diseases have long been a core part of its research portfolio. The new partnership extends that remit with dedicated funding.

What is the money for?

The £4.5 million partnership is directed at neglected tropical diseases, a World Health Organization-recognised category covering more than 20 conditions — including diseases such as schistosomiasis, lymphatic filariasis and river blindness — that collectively affect large numbers of people worldwide but historically receive a fraction of global R&D investment relative to disease burden.

According to the announcement, the partnership format signals joint work between LSTM and collaborating organisations, though the institution has not yet detailed in this release the specific partners, the disease targets selected, or the split of funding across research strands.

What should R&D managers watch next?

For research managers tracking NTD funding flows, the announcement raises practical questions that the accompanying detail — expected to follow from LSTM — should answer:

• Which specific diseases or product pipelines the £4.5 million will support;
• Who the partner organisations are and what each contributes;
• The timeframe of the programme and its milestones;
• Whether the funding covers early-stage discovery, translational work, or implementation research.

LSTM has not stated a start date for the programme beyond the announcement itself.

Why NTD partnerships matter for portfolio decisions

Neglected tropical diseases remain a structurally underfunded area of global health R&D. Partnerships of this scale — millions rather than billions — are the typical vehicle through which academic institutions, product development partnerships and funders assemble workable portfolios in this field.

A £4.5 million commitment is modest by pharmaceutical R&D standards but significant in the NTD context, where individual product development programmes often depend on pooled contributions of this size. The partnership model also spreads risk across institutions.

The announcement positions LSTM to deepen its NTD research pipeline. Further details on partners, disease targets and programme milestones are expected to follow the initial announcement.